FDA Approves Castration-Sensitive Prostate Cancer Drug

Article

Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.

Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.

Abiraterone acetate previously gained FDA approval in 2011 for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who had previously received chemotherapy. Additionally, the drug is indicated to treat patients with CRPC.

The new approval in CSPC was granted based on positive findings from the LATITUTDE clinical trial, which included 1199 patients with CSPC. Patients were randomized to receive abiraterone acetate 1000-mg plus prednisone 5-mg once daily or placebo. The FDA noted that patients in both cohorts were treated with gonadotropin-releasing hormone therapy or had a bilateral orchiectomy, according to the release.

For more information, visit SpecialtyPharmacyTimes.com.

Related Videos
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Image credit: motortion | stock.adobe.com - Young depressed woman talking to lady psychologist during session, mental health
Image credit:  JPC-PROD | stock.adobe.com - Choosing method of contraception : Birth control pills, an injection syringe, condom, IUD-method, on grey
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.